176 related articles for article (PubMed ID: 28887715)
1. Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas.
Chung LK; Pelargos PE; Chan AM; Demos JV; Lagman C; Sheppard JP; Nguyen T; Chang YL; Hojat SA; Prins RM; Liau LM; Nghiemphu L; Lai A; Cloughesy TF; Yong WH; Gordon LK; Wadehra M; Yang I
Brain Tumor Pathol; 2018 Jan; 35(1):1-9. PubMed ID: 28887715
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
[TBL] [Abstract][Full Text] [Related]
3. ACTC1 as an invasion and prognosis marker in glioma.
Ohtaki S; Wanibuchi M; Kataoka-Sasaki Y; Sasaki M; Oka S; Noshiro S; Akiyama Y; Mikami T; Mikuni N; Kocsis JD; Honmou O
J Neurosurg; 2017 Feb; 126(2):467-475. PubMed ID: 27081897
[TBL] [Abstract][Full Text] [Related]
4. DDX3X Biomarker Correlates with Poor Survival in Human Gliomas.
Hueng DY; Tsai WC; Chiou HY; Feng SW; Lin C; Li YF; Huang LC; Lin MH
Int J Mol Sci; 2015 Jul; 16(7):15578-91. PubMed ID: 26184164
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis.
Ljubimova JY; Lakhter AJ; Loksh A; Yong WH; Riedinger MS; Miner JH; Sorokin LM; Ljubimov AV; Black KL
Cancer Res; 2001 Jul; 61(14):5601-10. PubMed ID: 11454714
[TBL] [Abstract][Full Text] [Related]
6. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
[TBL] [Abstract][Full Text] [Related]
7. Tissue Proteome Analysis of Different Grades of Human Gliomas Provides Major Cues for Glioma Pathogenesis.
Gollapalli K; Ghantasala S; Atak A; Rapole S; Moiyadi A; Epari S; Srivastava S
OMICS; 2017 May; 21(5):275-284. PubMed ID: 28481733
[TBL] [Abstract][Full Text] [Related]
8. Expression and prognostic value of the WEE1 kinase in gliomas.
Music D; Dahlrot RH; Hermansen SK; Hjelmborg J; de Stricker K; Hansen S; Kristensen BW
J Neurooncol; 2016 Apr; 127(2):381-9. PubMed ID: 26738845
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of TELO2 decreases survival in human high-grade gliomas.
Feng SW; Chen Y; Tsai WC; Chiou HC; Wu ST; Huang LC; Lin C; Hsieh CC; Yang YJ; Hueng DY
Oncotarget; 2016 Jul; 7(29):46056-46066. PubMed ID: 27329594
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index.
Uematsu M; Ohsawa I; Aokage T; Nishimaki K; Matsumoto K; Takahashi H; Asoh S; Teramoto A; Ohta S
J Neurooncol; 2005 May; 72(3):231-8. PubMed ID: 15937645
[TBL] [Abstract][Full Text] [Related]
11. Impact of a novel biomarker, T-LAK cell-originating protein kinase (TOPK) expression on outcome in malignant glioma.
Hayashi T; Hayakawa Y; Koh M; Tomita T; Nagai S; Kashiwazaki D; Sugimori M; Origasa H; Kuroda S
Neuropathology; 2018 Apr; 38(2):144-153. PubMed ID: 29271010
[TBL] [Abstract][Full Text] [Related]
12. Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients.
Tu Y; He S; Fu J; Li G; Xu R; Lu H; Deng J
Clin Transl Oncol; 2012 Mar; 14(3):214-20. PubMed ID: 22374425
[TBL] [Abstract][Full Text] [Related]
13. Experimental validation of 5 in-silico predicted glioma biomarkers.
Towner RA; Jensen RL; Vaillant B; Colman H; Saunders D; Giles CB; Wren JD
Neuro Oncol; 2013 Dec; 15(12):1625-34. PubMed ID: 24158112
[TBL] [Abstract][Full Text] [Related]
14. NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas.
Vachher M; Arora K; Burman A; Kumar B
J Cell Biochem; 2020 Apr; 121(4):3010-3023. PubMed ID: 31710121
[TBL] [Abstract][Full Text] [Related]
15. ELTD1, a potential new biomarker for gliomas.
Towner RA; Jensen RL; Colman H; Vaillant B; Smith N; Casteel R; Saunders D; Gillespie DL; Silasi-Mansat R; Lupu F; Giles CB; Wren JD
Neurosurgery; 2013 Jan; 72(1):77-90; discussion 91. PubMed ID: 23096411
[TBL] [Abstract][Full Text] [Related]
16. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
17. Tenascin-C: a novel candidate marker for cancer stem cells in glioblastoma identified by tissue microarrays.
Nie S; Gurrea M; Zhu J; Thakolwiboon S; Heth JA; Muraszko KM; Fan X; Lubman DM
J Proteome Res; 2015 Feb; 14(2):814-22. PubMed ID: 25469866
[TBL] [Abstract][Full Text] [Related]
18. Deregulated expression of the clock genes in gliomas.
Chen Z; Liu P; Li C; Luo Y; Chen I; Liang W; Chen X; Feng Y; Xia H; Wang F
Technol Cancer Res Treat; 2013 Feb; 12(1):91-7. PubMed ID: 22905804
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
Garber ST; Hashimoto Y; Weathers SP; Xiu J; Gatalica Z; Verhaak RG; Zhou S; Fuller GN; Khasraw M; de Groot J; Reddy SK; Spetzler D; Heimberger AB
Neuro Oncol; 2016 Oct; 18(10):1357-66. PubMed ID: 27370400
[TBL] [Abstract][Full Text] [Related]
20. C-MET overexpression and amplification in gliomas.
Kwak Y; Kim SI; Park CK; Paek SH; Lee ST; Park SH
Int J Clin Exp Pathol; 2015; 8(11):14932-8. PubMed ID: 26823824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
